Ohio State is in the process of revising websites and program materials to accurately reflect compliance with the law. While this work occurs, language referencing protected class status or other activities prohibited by Ohio Senate Bill 1 may still appear in some places. However, all programs and activities are being administered in compliance with federal and state law.

CRB Investigator, Co-Founder of City Therapeutics, Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine

October 10, 2024

CRB Investigator, Co-Founder of City Therapeutics, Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine

Nakanishi

City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine

Harnessing next-generation siRNA engineering to improve and expand the therapeutic reach of RNAi-based medicines

Building sustainable product engine for innovative RNAi therapeutics to make a significant impact for patients across multiple disease indications, with first program expected to enter clinical development at or around year-end 2025

Led by founding Alnylam CEO and RNAi therapeutics pioneer John Maraganore, Ph.D., as executive chair and co-founded by key scientists and business leaders in RNAi

Financing led by ARCH Venture Partners with participation from Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures and AN Ventures

October 08, 2024 08:00 AM Eastern Daylight Time

CAMBRIDGE, Mass.--(BUSINESS WIRE)--City Therapeutics, Inc. announced its launch today with a vision to lead the future of RNA interference (RNAi)-based medicine. City Therapeutics™ aims to harness next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to build a robust and sustainable product engine and expand the therapeutic reach of RNAi-based medicines. Led by executive chair John Maraganore, Ph.D., founding CEO of Alnylam Pharmaceuticals, Inc., the company has completed a $135 million Series A financing led by ARCH Venture Partners, with participation from other leading life sciences investors including Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures and other undisclosed investors....read full story here